The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014

Abstract

BackgroundSince China has a unique system of delivering HIV care that includes all patients’ records. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART are understudied in the China despite subsequent virological suppression (viral load < 50 copies/mL) is unknown.MethodsThe authors conducted a retrospective cohort study using data from the national HIV treatment sub-database of Zhejiang province to identify records of HIV+ patients. Patient records were included if they were ≥ 16 years of age, had an initial CD4 count < 100 cells/μL, were on continuous HAART for at least one year by the end of December 31, 2014; and achieved and maintained continued maximum virological suppression (MVS) (< 50 copies/ml) by 9 months after starting HAART. The primary endpoint for analysis was time to first CD4+ T cell count recovery (≥ 200, 350, 500 cells/μL). Cox proportional hazard regression was used to identify the risk factors for CD4+ T cell count recovery to key thresholds (200–350, 350–500, ≥ 500 cells/μL) by the time of last clinical follow-up (whichever occurred first), key thresholds (follow-up date for analysis), with patients still unable to reach the endpoints being censored by the end December 31, 2014 (follow-up date for analysis).ResultsOf the 918 patients who were included in the study, and the median CD4+ T cell count was 39 cells/μL at the baseline. At the end of follow-up, 727 (79.2%), 363 (39.5%) and 149 (16.2%) patients had return to ≥ 200, 350, and 500 cells/μL, respectively. Kaplan-Meier analysis demonstrated that the rate of patients with CD4+ count recovery to ≥ 200, 350, and 500 cells/μL after 1 year on HAART was 43.6, 8.6, and 2.5%, respectively, after 3 years on treatment was 90.8, 46.3, and 17.9%, respectively, and after 5 years on HAART was 97.1, 72.2, and 36.4%, respectively. The median time to return to 200–350, 350–500, ≥ 500cells/μL was 1.11, 3.33 and 6.91 years, respectively. Factors of age (aHR = 0.77, 95%CI 0.61–0.97), baseline CD4+ count (aHR = 1.60, 95%CI 1.37–1.86), initial regimens, changes in regimen (aHR = 0.58, 95%CI 0.49–0.69), and inclusion of a cotrimoxazole prophylaxis (aHR = 0.66, 95%CI 0.51–0.85) were associated with CD4+ T cell count recovery.ConclusionThe proportion of patients with initially low CD4 counts after nine months of treatment and that achieved continuous virological suppression was greater than 70% for persons with CD4+ count ≥ 350. Conversely, only 35% of patients recovered to levels of 500 cells/μL after 5 years of treatment, and levels continued to rise significantly with further long-term HAART. Early HAART intervention will be necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

Mortality and treatment response amongst HIV-infected patients 50 years and older accessing antiretroviral services in South Africa

“…Our study also demonstrated that patients ≥50 years demonstrated poorer immununologic recovery on ART, as shown by poorer CD4+ cell count recovery, compared to younger patients. The slow CD4+ cell count recovery in our older cohort is consistent with other studies which indicate that older individuals have a lower rate of increase in CD4+ cell counts following ART exposure compared to younger individuals [ 22 ]. This ability to increase CD4 cell count determined the risk of death in the multivariable model [ 23 , 24 ].…”

Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment

“…Unlike other studies on IR [ 16 – 20 ], the present cohort study is limited to patients with sustained virological control to evaluate the immune systems’ maximum capacity to restore. So, patients were included if they: i) had a baseline count of aCD4, CD4% and CD4/CD8 collected ≤14 days prior to start ART; ii) received continuous ART for at least 1 year, iii) achieved an HIV-RNA <50 copies/ml during the first 24 weeks, and iv) maintained an undetectable viral load in ≥95% of the determinations throughout all the follow-up in order not to exclude subjects with occasional blips, defined as a positive viral load preceded and followed up by an undetectable viral load.…”

Reduction in HIV community viral loads following the implementation of a “Treatment as Prevention” strategy over 2 years at a population-level among men who have sex with men in Hangzhou, China

“…The following data were collected: date of HIV diagnosis, education and other social demographic characteristics, CD4 counts, transmission route, and routine follow-up and treatment information. The above databases have been described in detail in previous publications [ 24 , 25 ]. Prospective data were collected on patients who required VL testing in this study.…”